ReviewNature reviews. Urology2009
Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET.
Review in Nature reviews. Urology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 82 citations in OpenAlex.
- Value ofEuropean radiology · 2023Trial
- Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Trial
- Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2013Trial
- Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer.European journal of nuclear medicine and molecular imaging · 2013Trial
- Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer.Clinical nuclear medicine · 2012Trial
- Preclinical Evaluation of a Radiolabeled Anti-PSMA Dimeric Aptamer in a Murine Model of Human Prostate Cancer.Molecules (Basel, Switzerland) · 2026Article
- Effect of Dendritic Cells Injection After Radical Prostatectomy on Prostate Cancer in Mice.The Prostate · 2025Article
- From biology to the clinic - exploring liver metastasis in prostate cancer.Nature reviews. Urology · 2024Review
- Molecular Imaging of Monoamine Oxidase A Expression in Highly Aggressive Prostate Cancer: Synthesis and Preclinical Evaluation of Positron Emission Tomography Tracers.ACS pharmacology & translational science · 2023Article
- Role of volumetric parameters obtained fromAnnals of nuclear medicine · 2023Article
- Fluorine-18 Labeled Urea-Based Ligands Targeting Prostate-Specific Membrane Antigen (PSMA) with Increased Tumor and Decreased Renal Uptake.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Advances in the Biological Application of Force-Induced Remnant Magnetization Spectroscopy.Molecules (Basel, Switzerland) · 2022Review
- Application-specific nuclear medicalPhysics in medicine and biology · 2021Review
- Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality?Frontiers in oncology · 2021Review
- Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[Molecular imaging and biology · 2020Article
- Review
- Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities.Cold Spring Harbor perspectives in medicine · 2018Review
- Assessment of Bone Metastases in Patients with Prostate Cancer-A Comparison betweenPharmaceuticals (Basel, Switzerland) · 2017Article
- Positron emission tomography (PET) in primary prostate cancer staging and risk assessment.Translational andrology and urology · 2017Review
- PET imaging for lymph node dissection in prostate cancer.World journal of urology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Prostate cancer poses a major public health problem, particularly in the US and Europe, where it constitutes the most common type of malignancy among men, excluding nonmelanoma skin cancers. The disease is characterized by a wide spectrum of biological and clinical phenotypes, and its evaluation by imaging remains a challenge in view of this heterogeneity. Imaging in prostate cancer can be used in the initial diagnosis of the primary tumor, to determine the occurrence and extent of any extracapsular spread, for guidance in delivery and evaluation of local therapy in organ-confined disease, in locoregional lymph node staging, to detect locally recurrent and metastatic disease in biochemical relapse, to predict and assess tumor response to systemic therapy or salvage therapy, and in disease prognostication (in terms of the length of time taken for castrate-sensitive disease to become refractory to hormones and overall patient survival). Evidence from animal-based translational and human-based clinical studies points to a potential and emerging role for PET, using F-fluorodeoxyglucose as a radiotracer, in the imaging evaluation of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.